Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17825573 | 0.68 | ALDH1A1 (0.39) | ALDH1A1NPSR1CHEK1TSHRHTT | |
| Hydrochloric Acid SCHEMBL8486639 | 0.65 | GSK3A (0.36) | — | |
| SCHEMBL15416606 | 0.62 | — | — | |
| SCHEMBL3131376 | 0.61 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL3542407 | 0.61 | NPSR1 (0.41) | ALDH1A1NPSR1CHEK1TSHRHTT | |
| SCHEMBL15864201 | 0.60 | ALDH1A1 (0.39) | ALDH1A1NPSR1CHEK1TSHRHTT | |
| SCHEMBL1456727 | 0.55 | — | — | |
| SCHEMBL5752165 | 0.55 | — | — | |
| SCHEMBL8404455 | 0.55 | — | — | |
| Hypoxanthine SCHEMBL17276814 | 0.55 | ALDH1A1 (0.37) | ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3230467-A1 | METHODS AND COMPOSITIONS FOR DETECTING ANTIBIOTIC RESISTANT BACTERIA | ELITechGroup B.V. (NL) | 2017-10-18 | — | — | EP | claimed |
| WO-2016094162-A1 | METHODS AND COMPOSITIONS FOR DETECTING ANTIBIOTIC RESISTANT BACTERIA | ELITECHGROUP B.V. (NL) | 2016-06-16 | — | — | WO | claimed |
| US-8461165-B2 | 2-Substituted phenyl-5,7-dihydrocarbyl-3,7-dihydropyrrolo[2,3-d] pyrimidin-4-one derivatives, the preparation and the pharmaceutical use thereof | YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD (CN) | 2013-06-11 | — | — | US | disclosed |
| EP-1634883-B1 | 2-SUBSTITUTED PHENYL-5,7-DIALKYL-3,7-DIHYDROPYRROLE[2,3-D] PYRIMIDINE-4-ONE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF | YANGTZE RIVER PHARMACEUTICAL G (CN) | 2010-12-15 | — | — | EP | disclosed |
| US-20100204223-A1 | 2-Substituted phenyl-5,7-dihydrocarbyl-3,7-dihydropyrrolo[2,3-d] pyrimidin-4-one derivatives, the preparation and the pharmaceutical use thereof | YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD. (CN) | 2010-08-12 | — | — | US | disclosed |
| US-7745433-B2 | 2-Substituted phenyl-5, 7-dihydrocarbyl-3, 7-dihydropyrrolo [2, 3-D] pyrimidin-4-one derivatives, the preparation and the pharmaceutical use thereof | Yangtze River Pharmacuetical (Group) Co., Ltd. (CN) | 2010-06-29 | — | — | US | disclosed |
| US-7741483-B2 | Process for making substituted pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of phosphodiesterase 5 | YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD. (CN) | 2010-06-22 | — | — | US | disclosed |
| US-20080167462-A1 | 2-substituted phenyl-5, 7-dehydrocarbyl-3, 7-dihydropyrrolo [2, 3-d] pyrimidin-4-one derivatives, the preparation and the pharmaceutical use thereof | TIANJIN TASLY GROUP CO., LTD (CN) | 2008-07-10 | — | — | US | disclosed |
| US-20060173025-A1 | 2-Substituted phenyl-5,7-dialkyl-3,7-dihydropyrrole [2,3-d]pyrimidine-4-one derivatives, the preparation and the pharmaceutical use thereof | YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD. (CN) | 2006-08-03 | — | — | US | disclosed |
| EP-1634883-A1 | 2-SUBSTITUTED PHENYL-5,7-DIALKYL-3,7-DIHYDROPYRROLE[2,3-D]PYRIMIDINE-4-ONE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF | Tianjin Tasly Group Co., Ltd. (CN) | 2006-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167462-A1 | 2-substituted phenyl-5, 7-dehydrocarbyl-3, 7-dihydropyrrolo [2, 3-d] pyrimidin-4-one derivatives, the preparation and the pharmaceutical use thereof | PDE5A, PDE3B, PDE2A | ALDH1A1 681/4885NPSR1 2545/4885CHEK1 3121/4885 |
| US-20060173025-A1 | 2-Substituted phenyl-5,7-dialkyl-3,7-dihydropyrrole [2,3-d]pyrimidine-4-one derivatives, the preparation and the pharmaceutical use thereof | PDE5A, PDE3B, PDE2A | ALDH1A1 1203/4885NPSR1 810/4885CHEK1 2512/4885 |
| US-20100204223-A1 | 2-Substituted phenyl-5,7-dihydrocarbyl-3,7-dihydropyrrolo[2,3-d] pyrimidin-4-one derivatives, the preparation and the pharmaceutical use thereof | PDE5A, PDE3A, PDE2A | ALDH1A1 762/4885NPSR1 2192/4885CHEK1 3374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.